An Advancement in Ovarian Cancer Surgery
CYTALUX™ is the first-ever targeted imaging agent designed to “highlight” ovarian cancer in the body, helping surgeons to see it in real-time, as they operate. As you can imagine, an added measure of visibility in the operating room can help the surgeon find cancer that may have otherwise been missed.
How CYTALUX Works:
1-9 hours prior to surgery, CYTALUX is administered to patients through intravenous infusion as part of their preoperative care.
CYTALUX contains a folic acid analog (a type of folic acid) that identifies and binds to the folate receptors on ovarian cancer cells.
CYTALUX contains a dye that lights up when a special camera, called a near-infrared imaging system, is used during surgery (think of it as ink that only shows up under black light).
CYTALUX Gives Your Doctor an Advantage
Surgery is a common treatment for ovarian cancer. With CYTALUX on your side, there is an increased chance your surgeon can find additional ovarian cancer that may not have been detected otherwise.
Increasing the likelihood of detection
In a clinical trial, CYTALUX was proven to help surgeons find and remove additional ovarian cancer that would have otherwise gone undetected in 27% of patients.
Safety data is supported by 3 clinical studies across 294 patients. The most common side effects of CYTALUX reported across the clinical trials were nausea (15%), vomiting (5.8%), abdominal pain (2.7%), flushing (1.7%), indigestion (1%), chest discomfort (1%), itching (1%), and allergic reaction (1%) during administration or infusion.
During the Phase 3 clinical study, there were zero serious drug-related adverse events reported and 97% of drug-related adverse events were mild or moderate.